This open-label, randomized controlled trial aimed to investigate the effect of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock.
Terlipressin is a synthetic vasopressin analog with great affinity to the V1 receptor (vasoconstrictive effect), and could selectively contract efferent arterioles, increase glomerular filtration pressure and renal perfusion. The investigators conducted this open-label, randomized controlled trial to observe the effects of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock. Renal perfusion was monitored by renal contrast-enhanced ultrasound. The primary outcome was peak intensity (renal perfusion parameter) at 24 hours after enrollment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
Nanjing Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China
Peak intensity
Peak intensity is the peak concentration of contrast agent, a kind of renal perfusion parameter monitored by renal contrast-enhanced ultrasound.
Time frame: 24 hours after enrollment
urine output, mL
urine output with 24 hours
Time frame: 24 hours after enrollment
The incidence of acute kidney injury
Defined as serum creatinine increase≥50% within seven days or increase≥26.5 μmol/L within 48 hours
Time frame: Within 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.